Resveratrol inhibits monocytic cell chemotaxis to MCP-1 and prevents spontaneous endothelial cell migration through Rho kinase-dependent mechanism

Journal of Atherosclerosis and Thrombosis

Volumn 18, Issue 12, 2011, Pages 1031-1042

  Cicha, Iwona ^a   Regler, Melanie ^a   Urschel, Katharina ^a   Goppelt Struebe, Margarete ^a   Daniel, Werner G ^a   Garlichs, Christoph D ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Endothelial cell migration; Monocyte chemotaxis; Resveratrol; RhoA; ROCK inhibition

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; CHEMOKINE RECEPTOR CCR2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATASE; RESVERATROL; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIRTUIN 1;

ARTICLE; CELL ELONGATION; CELL SHAPE; CHEMOTAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; HUMAN; HUMAN CELL; MIGRATION INHIBITION; MONOCYTIC CELL CHEMOTAXIS; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; UMBILICAL VEIN ENDOTHELIAL CELL;

BLOTTING, WESTERN; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOTAXIS, LEUKOCYTE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HUMANS; MONOCYTES; PHOSPHORYLATION; RHO-ASSOCIATED KINASES; STILBENES;

EID: 84455183070     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.8136     Document Type: Article

References (38)

1. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med, 2005; 352: 1685-1695
2. Weber C, Zernecke A, Libby P: The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immuno, 2008; 8: 802-815
3. Liehn EA, Zernecke A, Postea O, Weber C: Chemokines: inflammatory mediators of atherosclerosis. Arch Physiol Biochem, 2006; 112: 229-238
4. Le Dall J, Ho-Tin-Noé B, Louedec L, Meilhac O, Roncal C, Carmeliet P, Germain S, Michel JB, Houard X: Immaturity of microvessels in haemorrhagic plaques is associated with proteolytic degradation of angiogenic factors. Cardiovasc Res, 2010; 85: 184-193
5. McCarthy MJ, Loftus IM, Thompson MM, Jones L, London NJ, Bell PR, Naylor AR, Brindle NP: Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. J Vasc Surg, 1999; 30: 261-268
6. Opie LH, Lecour S: The red wine hypothesis: from concepts to protective signalling molecules. Eur Heart J, 2007; 28: 1683-1693
7. Csiszar A, Smith K, Labinskyy N, Orosz Z, Rivera A, Ungvari Z: Resveratrol attenuates TNF-α-induced activation of coronary arterial endothelial cells: role of NF-κB inhibition. Am J Physiol Heart Circ Physiol, 2006; 291: H1694-H1699
8. Rakici O, Kiziltepe U, Coskun B, Aslamaci S, Akar F: Effects of resveratrol on vascular tone and endothelial function of human saphenous vein and internal mammary artery. Int J Cardiol, 2005; 105: 209-215
9. Gracia-Sancho J, Villarreal G Jr, Zhang Y, García-Cardeña G: Activation of SIRT1 by resveratrol induces KLF2 expression conferring an endothelial vasoprotective phenotype. Cardiovasc Res, 2010; 85: 514-519
10. Cicha I, Beronov K, Lopez Ramirez E, Osterode K, Goppelt-Struebe M, Raaz D, Yilmaz A, Daniel WG, Garlichs CD: Shear stress preconditioning modulates endothelial susceptibility to circulating TNF-α and monocytic cell recruitment in a simplified model of arterial bifurcations. Atherosclerosis, 2009; 207: 93-102
11. Azios NG, Dharmawardhane SF: Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells. Neoplasia, 2005; 7: 128-140
12. Kimura Y, Sumiyoshi M, Baba K: Antitumor activities of synthetic and natural stilbenes through antiangiogenic action. Cancer Sci, 2008; 99: 2083-2096
13. Jakobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z: Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA, 1991; 88: 3628-3632
14. Cicha I, Yilmaz A, Klein M, Raithel D, Brigstock DR, Daniel WG, Goppelt-Struebe M, Garlichs CD: Connective tissue growth factor is overexpressed in complicated atherosclerotic plaques and induces mononuclear cell chemotaxis in vitro. Arterioscler Thromb Vasc Biol, 2005; 25: 1008-1013
15. Tamma G, Klussmann E, Procino G, Svelto M, Rosenthal W, Valenti G: cAMP-induced AQP2 translocation is associated with RhoA inhibition through RhoA phosphorylation and interaction with RhoGDI. J Cell Sci, 2003; 116: 1519-1525
16. Kroll J, Epting D, Kern K, Dietz CT, Feng Y, Hammes HP, Wieland T, Augustin HG: Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis. Am J Physiol Heart Circ Physiol, 2009; 296: H893-H899
17. Mason JC: Statins and their role in vascular protection. Clin Sci (Lond), 2003; 105: 251-266
18. Cullen JP, Morrow D, Jin Y, von Offenberg Sweeney N, Sitzmann JV, Cahill PA, Redmond EM: Resveratrol inhibits expression and binding activity of the monocyte chemotactic protein-1 receptor, CCR2, on THP-1 monocytes. Atherosclerosis, 2007; 195: e125-e133
19. Jiménez-Sainz MC, Fast B, Mayor F Jr, Aragay AM: Signaling pathways for monocyte chemoattractant protein 1-mediated extracellular signal-regulated kinase activation. Mol Pharmacol, 2003; 64: 773-782
20. Norata GD, Marchesi P, Passamonti S, Pirillo A, Violi F, Catapano AL: Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. Atherosclerosis, 2007; 191: 2 65-271
21. Fan E, Zhang L, Jiang S, Bai Y: Beneficial effects of resveratrol on atherosclerosis. J Med Food, 2008; 11: 610-614
22. Inanaga K, Ichiki T, Matsuura H, Miyazaki R, Hashimoto T, Takeda K, Sunagawa K: Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis. Hypertens Res, 2009; 32: 466-471
23. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J: Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation, 1999; 99: 1726-1732
24. Ganaha F, Kao EY, Wong H, Elkins CJ, Lee J, Modanlou S, Rhee C, Kuo MD, Yuksel E, Cifra PN, Waugh JM, Dake MD: Stent-based controlled release of intravascular angiostatin to limit plaque progression and in-stent restenosis. J Vasc Interv Radiol, 2004; 15: 601-608
25. Stefanadis C, Toutouzas K, Stefanadi E, Tsiamis E, Vavuranakis M, Kipshidze N: Avastin-eluting stent: longterm angiographic and clinical follow up. Hellenic J Cardiol, 2008; 49: 188-190
26. Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman EA, Caldwell SD, Napper A, Curtis R, DiStefano PS, Fields S, Bedalov A, Kennedy BK: Substrate-specific activation of sirtuins by resveratrol. J Biol Chem, 2005; 280: 17038-17045
27. Guarani V, Potente M: SIRT1- a metabolic sensor that controls blood vessel growth. Curr Opin Pharmacol, 2010; 10: 139-145
28. Potente M, Ghaeni L, Baldessari D, Mostoslavsky R, Rossig L, Dequiedt F, Haendeler J, Mione M, Dejana E, Alt FW, Zeiher AM, Dimmeler S: SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev, 2007; 21: 2644-2658
29. Zhang Y, Zhang M, Dong H, Yong S, Li X, Olashaw N, Kruk PA, Cheng JQ, Bai W, Chen J, Nicosia SV, Zhang X: Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene, 2009; 28: 445-460
30. Khan AA, Dace DS, Ryazanov AG, Kelly J, Apte RS: Resveratrol regulates pathologic angiogenesis by a eukaryotic elongation factor-2 kinase-regulated pathway. Am J Pathol, 2010; 177: 481-492
31. Lin HY, Lansing L, Merillon JM, Davis FB, Tang HY, Shih A, Vitrac X, Krisa S, Keating T, Cao HJ, Bergh J, Quackenbush S, Davis PJ: Integrin αVβ3 contains a receptor site for resveratrol. FASEB J, 2006; 20: 1742-1744
32. Belleri M, Ribatti D, Savio M, Stivala LA, Forti L, Tanghetti E, Alessi P, Coltrini D, Bugatti A, Mitola S, Nicoli S, Vannini V, Presta M: Alphavbeta3 Integrin-dependent antiangiogenic activity of resveratrol stereoisomers. Mol Cancer Ther, 2008; 7: 3761-3770
33. Je HD, Lee MH, Jeong JH, Park SY, Sohn UD: Protective effect of resveratrol on agonist-dependent regulation of vascular contractility via inhibition of rho-kinase activity. Pharmacology, 2010; 86: 37-43
34. Ishibashi M, Hiasa K, Zhao Q, Inoue S, Ohtani K, Kitamoto S, Tsuchihashi M, Sugaya T, Charo IF, Kura S, Tsuzuki T, Ishibashi T, Takeshita A, Egashira K: Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res, 2004; 94: 1203-1210
35. Ohman MK, Wright AP, Wickenheiser KJ, Luo W, Russo HM, Eitzman DT: Monocyte chemoattractant protein-1 deficiency protects against visceral fat-induced atherosclerosis. Arterioscler Thromb Vasc Biol, 2010, in press, DOI: 10.1161/ATVBAHA.110.205914
36. Cullen JP, Morrow D, Jin Y, Curley B, Robinson A, Sitzmann JV, Cahill PA, Redmond EM: Resveratrol, a polyphenolic phytostilbene, inhibits endothelial monocyte chemotactic protein-1 synthesis and secretion. J Vasc Res, 2007; 44: 75-84
37. de Santi C, Pietrabissa A, Spisni R, Mosca F, Pacific GM: Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica, 2000; 30: 1047-1054
38. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res, 2004; 24: 2783-2840